Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Pfizer
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05905341CT.gov Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | — | Withdrawn | — | — | — |
NCT04557449CT.gov Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liposarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | Pfizer | P2 | B · 60 |
| Letrozole | Pfizer | P2 | CCC |
| Enzalutamide | Pfizer | P2 | CCC |
| Atirmociclib | Pfizer | P2 | CCC |
| Midazolam | Pfizer | P2 | CCC |
| Zovostotug | OncoResponse, Inc. | P1/2 | CC |
| Apg 115 | Ascentage Pharma Group Inc. | P1/2 | CC |
| Docetaxel | OncoResponse, Inc. | P1/2 | CC |
| Silmitasertib | Milton S. Hershey Medical Center | P1/2 | CC |
+11 more in the Liposarcoma cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Liposarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-liposarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →